Study Number:	I10482
Study Gender:	Female
PWG Approval Date:	See web page for date of PWG Approval
Version:	v1.4.1
Stat Version:	v2.8.4A

Study Number: I10482
Test Type: TOX
Route: Dosing in Feed
Species/Strain: Mouse/B6C3F1/N

I04: Mean Body Weight Summary
Test Compound: N-Butylbenzenesulfonamide
CAS Number: 3622-84-2

Date Report Requested: 04/14/2022
Time Report Requested: 07:45:20
Lab: Burleson Research Technologies

Females: SRBC

	Treatment Groups (ppm)										
Phase Day	**0**		**313**			**625**			**1250**		
	Wt (g)	**N**	**Wt (g)**	**% from CNTL**	**N**	**Wt (g)**	**% from CNTL**	**N**	**Wt (g)**	**% from CNTL**	**N**
SD0	21.4 ± 0.4	8	20.9 ± 0.4	-2.4	8	20.8 ± 0.5	-3.2	8	20.2 ± 0.4	-5.9	8
SD7	22.1 ± 0.5	8	21.8 ± 0.7	-1.6	8	21.4 ± 0.5	-3.1	8	20.8 ± 0.3	-6.0	8
SD14	23.2 ± 0.5 *	8	22.3 ± 0.5	-3.8	8	22.4 ± 0.6	-3.7	8	21.5 ± 0.6	-7.3	8
SD21	24.2 ± 0.8	8	23.4 ± 0.6	-3.3	8	22.6 ± 0.5	-6.5	8	22.1 ± 0.4 *	-8.8	8
SD28	24.7 ± 0.6	8	24.0 ± 1.0	-2.7	8	23.5 ± 0.6	-5.0	8	22.8 ± 0.5	-7.4	8

Study Number: I10482
Test Type: TOX
Route: Dosing in Feed
Species/Strain: Mouse/B6C3F1/N

I04: Mean Body Weight Summary
Test Compound: N-Butylbenzenesulfonamide
CAS Number: 3622-84-2

Date Report Requested: 04/14/2022
Time Report Requested: 07:45:20
Lab: Burleson Research Technologies

Females: SRBC

Phase Day	Treatment Groups (ppm)								
	2500			5000			50 mg/kg CPS		
	Wt (g)	% from CNTL	N	Wt (g)	% from CNTL	N	Wt (g)	% from CNTL	N
SD0	21.3 ± 0.5	-0.5	8	20.8 ± 0.6	-2.8	8	20.8 ± 0.5	-3.2	8
SD7	22.0 ± 0.5	-0.6	8	21.1 ± 0.5	-4.7	8	21.6 ± 0.5	-2.5	8
SD14	22.6 ± 0.3	-2.5	8	21.2 ± 0.5 *	-8.7	8	22.5 ± 0.5	-2.9	8
SD21	23.6 ± 0.5	-2.3	8	22.1 ± 0.5	-8.6	8	24.0 ± 0.6	-0.8	8
SD28	24.8 ± 0.5	0.7	8	22.5 ± 0.5	-8.7	8	23.5 ± 0.7	-5.0	8

Study Number: I10482
Test Type: TOX
Route: Dosing in Feed
Species/Strain: Mouse/B6C3F1/N

I04: Mean Body Weight Summary
Test Compound: N-Butylbenzenesulfonamide
CAS Number: 3622-84-2

Date Report Requested: 04/14/2022
Time Report Requested: 07:45:20
Lab: Burleson Research Technologies

Females: KLH

	Treatment Groups (ppm)										
Phase Day	**0**		**313**			**625**			**1250**		
	Wt (g)	**N**	**Wt (g)**	**% from CNTL**	**N**	**Wt (g)**	**% from CNTL**	**N**	**Wt (g)**	**% from CNTL**	**N**
SD0	20.3 ± 0.4 *	8	20.9 ± 0.4	2.8	8	20.8 ± 0.4	2.1	8	20.9 ± 0.5	3.0	8
SD7	21.7 ± 0.5 **	8	22.1 ± 0.4	2.2	8	21.4 ± 0.5	-1.2	8	21.4 ± 0.4	-1.0	8
SD14	22.5 ± 0.6 **	8	23.1 ± 0.5	3.0	8	22.7 ± 0.4	1.1	8	22.7 ± 0.6	1.2	8
SD21	23.2 ± 0.7 **	8	23.0 ± 0.4	-1.2	8	23.0 ± 0.5	-1.1	8	23.2 ± 0.7	-0.2	8
SD28	24.3 ± 1.0 **	8	24.3 ± 0.4	0.0	8	24.3 ± 0.6	-0.1	8	23.9 ± 0.9	-1.7	8

Study Number: I10482
Test Type: TOX
Route: Dosing in Feed
Species/Strain: Mouse/B6C3F1/N

I04: Mean Body Weight Summary
Test Compound: N-Butylbenzenesulfonamide
CAS Number: 3622-84-2

Date Report Requested: 04/14/2022
Time Report Requested: 07:45:20
Lab: Burleson Research Technologies

Females: KLH

Phase Day	Treatment Groups (ppm)								
	2500			5000			50 mg/kg CPS		
	Wt (g)	% from CNTL	N	Wt (g)	% from CNTL	N	Wt (g)	% from CNTL	N
SD0	19.8 ± 0.3	-2.8	8	19.5 ± 0.3	-4.1	8	20.6 ± 0.4	1.4	8
SD7	20.5 ± 0.2	-5.5	8	19.7 ± 0.3 **	-8.8	8	21.2 ± 0.3	-2.1	8
SD14	21.6 ± 0.3	-4.0	8	20.6 ± 0.3 **	-8.2	8	22.1 ± 0.4	-1.6	8
SD21	21.9 ± 0.4	-5.6	8	20.7 ± 0.3 **	-10.9	8	21.5 ± 0.4	-7.4	8
SD28	22.8 ± 0.4	-6.0	8	21.5 ± 0.3 **	-11.4	8	21.9 ± 0.4 *	-9.7	8

Study Number: I10482
Test Type: TOX
Route: Dosing in Feed
Species/Strain: Mouse/B6C3F1/N

I04: Mean Body Weight Summary
Test Compound: N-Butylbenzenesulfonamide
CAS Number: 3622-84-2

Date Report Requested: 04/14/2022
Time Report Requested: 07:45:20
Lab: Burleson Research Technologies

Females: Immunophenotyping

	Treatment Groups (ppm)										
Phase Day	**0**		**313**			**625**			**1250**		
	Wt (g)	**N**	**Wt (g)**	**% from CNTL**	**N**	**Wt (g)**	**% from CNTL**	**N**	**Wt (g)**	**% from CNTL**	**N**
SD0	20.6 ± 0.4	8	21.7 ± 0.5	5.2	8	21.3 ± 0.4	3.4	8	21.6 ± 0.3	4.9	8
SD7	21.9 ± 0.4	8	22.5 ± 0.7	2.7	8	21.6 ± 0.3	-1.4	8	22.3 ± 0.4	1.8	8
SD14	22.8 ± 0.4	8	23.3 ± 0.9	2.0	8	22.9 ± 0.3	0.1	8	23.5 ± 0.4	2.9	8
SD21	23.4 ± 0.6	8	24.6 ± 1.1	5.3	8	23.9 ± 0.6	2.2	8	24.2 ± 0.5	3.4	8
SD28	24.7 ± 0.7	8	25.8 ± 1.2	4.6	8	24.9 ± 0.4	0.9	8	25.2 ± 0.4	2.1	8

Study Number: I10482
Test Type: TOX
Route: Dosing in Feed
Species/Strain: Mouse/B6C3F1/N

I04: Mean Body Weight Summary
Test Compound: N-Butylbenzenesulfonamide
CAS Number: 3622-84-2

Date Report Requested: 04/14/2022
Time Report Requested: 07:45:20
Lab: Burleson Research Technologies

Females: Immunophenotyping

Phase Day	Treatment Groups (ppm)								
	2500			5000			50 mg/kg CPS		
	Wt (g)	% from CNTL	N	Wt (g)	% from CNTL	N	Wt (g)	% from CNTL	N
SD0	21.2 ± 0.5	3.2	8	21.4 ± 0.3	3.8	8	21.4 ± 0.6	3.9	8
SD7	21.9 ± 0.4	0.1	8	21.4 ± 0.4	-2.4	8	21.8 ± 0.5	-0.2	8
SD14	22.9 ± 0.7	0.1	8	21.9 ± 0.3	-4.1	8	22.6 ± 0.6	-1.0	8
SD21	23.5 ± 0.7	0.4	8	22.2 ± 0.4	-5.1	8	23.2 ± 0.6	-0.6	8
SD28	24.8 ± 0.7	0.6	8	22.9 ± 0.5	-7.2	8	23.8 ± 0.6	-3.7	8

Study Number: I10482
Test Type: TOX
Route: Dosing in Feed
Species/Strain: Mouse/B6C3F1/N

I04: Mean Body Weight Summary
Test Compound: N-Butylbenzenesulfonamide
CAS Number: 3622-84-2

Date Report Requested: 04/14/2022
Time Report Requested: 07:45:20
Lab: Burleson Research Technologies

Females: CTL

	Treatment Groups (ppm)										
Phase Day	**0**		**313**			**625**			**1250**		
	Wt (g)	**N**	**Wt (g)**	**% from CNTL**	**N**	**Wt (g)**	**% from CNTL**	**N**	**Wt (g)**	**% from CNTL**	**N**
SD0	20.5 ± 0.3	8	20.6 ± 0.4	0.6	8	20.6 ± 0.4	0.4	8	20.6 ± 0.4	0.5	8
SD7	21.4 ± 0.3	8	20.7 ± 0.4	-3.0	8	20.9 ± 0.6	-2.3	8	21.4 ± 0.5	-0.1	8
SD14	22.4 ± 0.3 *	8	22.3 ± 0.4	-0.5	8	21.8 ± 0.3	-2.8	8	22.5 ± 0.5	0.2	8
SD21	22.8 ± 0.5	8	22.7 ± 0.4	-0.2	8	22.0 ± 0.4	-3.2	8	22.8 ± 0.5	0.1	8
SD28	22.8 ± 0.6 *	8	23.2 ± 0.4	1.8	8	22.3 ± 0.6	-2.2	8	23.8 ± 0.5	4.2	8

Study Number: I10482
Test Type: TOX
Route: Dosing in Feed
Species/Strain: Mouse/B6C3F1/N

I04: Mean Body Weight Summary
Test Compound: N-Butylbenzenesulfonamide
CAS Number: 3622-84-2

Date Report Requested: 04/14/2022
Time Report Requested: 07:45:20
Lab: Burleson Research Technologies

Females: CTL

Phase Day	Treatment Groups (ppm)								
	2500			5000			50 mg/kg CPS		
	Wt (g)	% from CNTL	N	Wt (g)	% from CNTL	N	Wt (g)	% from CNTL	N
SD0	20.7 ± 0.3	1.0	8	20.8 ± 0.4	1.4	8	20.9 ± 0.4	1.8	8
SD7	21.1 ± 0.3	-1.3	8	20.8 ± 0.4	-2.9	8	21.5 ± 0.4	0.4	8
SD14	21.9 ± 0.2	-2.4	8	21.5 ± 0.4	-4.3	8	22.2 ± 0.6	-1.0	8
SD21	22.4 ± 0.2	-1.7	8	21.9 ± 0.4	-4.1	8	22.8 ± 0.6	0.2	7
SD28	22.0 ± 0.3	-3.6	8	20.3 ± 0.7 *	-10.8	8	20.2 ± 0.7 *	-11.5	7

Study Number: I10482
Test Type: TOX
Route: Dosing in Feed
Species/Strain: Mouse/B6C3F1/N

I04: Mean Body Weight Summary
Test Compound: N-Butylbenzenesulfonamide
CAS Number: 3622-84-2

Date Report Requested: 04/14/2022
Time Report Requested: 07:45:20
Lab: Burleson Research Technologies

Females: Immunopath

	Treatment Groups (ppm)										
Phase Day	**0**		**313**			**625**			**1250**		
	Wt (g)	**N**	**Wt (g)**	**% from CNTL**	**N**	**Wt (g)**	**% from CNTL**	**N**	**Wt (g)**	**% from CNTL**	**N**
SD0	21.2 ± 0.3	8	20.7 ± 0.3	-2.5	8	20.9 ± 0.4	-1.7	8	20.7 ± 0.3	-2.2	8
SD7	21.3 ± 0.3	8	20.5 ± 0.3	-3.4	8	21.2 ± 0.5	-0.2	8	20.7 ± 0.3	-2.5	8
SD14	22.2 ± 0.4	8	21.2 ± 0.4	-4.1	8	21.9 ± 0.5	-1.4	8	21.8 ± 0.3	-1.4	8
SD21	23.6 ± 0.6	8	22.0 ± 0.4	-6.9	8	22.3 ± 0.6	-5.4	8	23.5 ± 0.4	-0.3	8
SD28	23.6 ± 0.5	8	22.5 ± 0.4	-4.8	8	23.4 ± 0.7	-1.1	8	23.9 ± 0.5	1.3	8

Study Number: I10482
Test Type: TOX
Route: Dosing in Feed
Species/Strain: Mouse/B6C3F1/N

I04: Mean Body Weight Summary
Test Compound: N-Butylbenzenesulfonamide
CAS Number: 3622-84-2

Date Report Requested: 04/14/2022
Time Report Requested: 07:45:20
Lab: Burleson Research Technologies

Females: Immunopath

Phase Day	Treatment Groups (ppm)								
	2500			5000			50 mg/kg CPS		
	Wt (g)	% from CNTL	N	Wt (g)	% from CNTL	N	Wt (g)	% from CNTL	N
SD0	21.3 ± 0.4	0.6	8	21.6 ± 0.4	2.0	8	21.5 ± 0.4	1.5	8
SD7	21.0 ± 0.4	-1.4	8	20.9 ± 0.3	-1.5	8	21.5 ± 0.4	1.2	8
SD14	22.2 ± 0.5	0.1	8	21.3 ± 0.3	-4.0	8	22.3 ± 0.5	0.6	8
SD21	23.1 ± 0.6	-1.9	8	21.8 ± 0.3	-7.6	8	23.3 ± 0.6	-1.2	8
SD28	23.9 ± 0.5	1.1	8	22.5 ± 0.4	-4.8	8	23.7 ± 0.7	0.2	8

LEGEND

Data are displayed as mean ± SEM
SD – Study Day
Statistical analysis of weight data performed by Jonckheere (trend) and Williams or Dunnett (pairwise) tests.
Statistical analysis for the positive control group compared to the vehicle control group was performed using the t-Test.
Statistical significance for the control group indicates a significant trend test
Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group
* Statistically significant at P <= 0.05
** Statistically significant at P <= 0.01
CPS = Cyclophosphamide

** END OF REPORT **